Publication of the First Quarter Interim Statement (as at March 30, 2012)
Annual General Meeting
Publication of the First Semester Interim Statement (as at June 30, 2012)
Publication of the Third Quarter Statement (as at September 30, 2012)
IBA is listed on the pan-European stock exchange EURONEXT.
As of April 2 2012, IBA created a strategic alliance with SK Capital Partners to create IBA Molecular, world leader in the Nuclear medicine market.
IBA MolecularING: Matthias Maenhaut
KBC Securities: Jan De Kerpel
Petercam: Jan Van den Bossche
© IBA 2012 | All rights reserved |
Site map |
